CHAMPIONS ONCOLOGY, INC. (CSBR) Form 8-K — Sep 10, 2026
Champions Oncology reported first-quarter fiscal 2027 revenue of $15.2 million, up 8.8% year over year, driven by improved conversion of contracted work in core research services and increased data license revenue. Profitability improved markedly: oncology services margin expanded to 51% from 43% a year ago on lower third-party radiolabeling costs, Adjusted EBITDA rose to $671,000 from $59,000, and the GAAP net loss narrowed to $426,000 from $466,000. The company ended the quarter with approximately $4.4 million of cash and no debt, though sales and marketing spend jumped 66.6% to $3.1 million as it invests in its commercial organization, data platform, and radiopharmaceutical capabilities.
Key figures
- Revenue
- 15232000
- Total Debt
- 0
- Revenue Yoy
- 8.8%
- Total Assets
- 33290000
- Cash Position
- 4358000
- Rnd Expense
- 2344000
- Adjusted EBITDA
- 671000
- Deferred Revenue
- 9552000
- Adjusted Eps Basic
- 0.05
- Cost Of Oncology Revenue
- 7534000
- Oncology Services Margin
- 51%
- Weighted Avg Shares Basic
- 13897535
- Prior Year Adjusted EBITDA
- 59000
- Sales And Marketing Expense
- 3090000
- Prior Year Oncology Services Margin
- 43%
Price after filing
Close on the filing date to close N calendar days later (from $5.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.